Cancer diagnostics are changing rapidly, and Qlucore is at the forefront of this development. The Qlucore software, unique in its field, combines advanced visualization, AI-based machine learning and biology to improve performance as well as ease of use and speed. Qlucore Insights leverages whole transcriptomic data generated through next-generation sequencing to derive results. The solution is easy to deploy as it is based on basic lab workflows and instruments. The program operates on-premises, ensuring enhanced data security.

Lung cancer remains one of the most challenging diseases to diagnose and treat effectively. With Qlucore Insights, Mubadala Health Dubai aims to improve lung cancer diagnostics.

"Our solution will facilitate and enable analysis of cancer samples. The goal is to make it easier for the doctor to make a diagnosis and decide how the disease should be treated, and for the patients to receive more precise treatment,” says Carl-Johan Ivarsson, CEO of Qlucore.

In addition to Qlucore Insights test for lung cancer samples, Mubadala Health Dubai has also purchased Qlucore Insights for analysis of pediatric leukemia (BCP-ALL). This dual application underscores the versatility and robustness of Qlucore's software in addressing various cancer types.

Qlucore Insights is for research use only.